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Abstract
Background: Litchi seeds possess rich amounts of phenolics and have been shown to inhibit proliferation of
several types of cancer cells. However, the suppression of EGFR signaling in non-small cell lung cancer (NSCLC) by
litchi seed extract (LCSE) has not been fully understood.
Methods: In this study, the effects of LCSE on EGFR signaling, cell proliferation, the cell cycle and apoptosis in A549
adenocarcinoma cells and NCI- H661 large-cell carcinoma cells were examined.
Results: The results demonstrated that LCSE potently reduced the number of cancer cells and induced growth
inhibition, cell-cycle arrest in the G1 or G2/M phase, and apoptotic death in the cellular experiment. Only low
cytotoxicity effect was noted in normal lung MRC-5 cells. LCSE also suppressed cyclins and Bcl-2 and elevated
Kip1/p27, Bax and caspase 8, 9 and 3 activities, which are closely associated with the downregulation of EGFR
and its downstream Akt and Erk-1/-2 signaling.
Conclusion: The results implied that LCSE suppressed EGFR signaling and inhibited NSCLC cell growth. This study
provided in vitro evidence that LCSE could serve as a potential agent for the adjuvant treatment of NSCLC.
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Background
Lung cancer is the most threatening type of cancer in
industrial countries, with high morbidity and mortality,
because many patients are diagnosed with advanced
disease [1]. Non-small cell lung cancer (NSCLC) is the
most prevalent type of lung malignancy. Although recent
advancements in treatment strategies using tyrosine kin-
ase inhibitors (TKIs) to treat NSCLC have been developed
to prolong patient survival by 3-fold as compared to trad-
itional chemotherapies, drug resistance still occurs in a
proportion of patients. Other adjuvant strategies to pro-
long the survival rate of NSCLC patients administered
TKIs should be developed [2–4]. Litchi (Litchi chinensis,
Sapindaceae) is a warm-climate fruit tree that originates
from southern China and is cultivated in semi-tropical
areas of the world for its delicious fruit [5]. In traditional
Chinese herbal medicine, the function of litchi seeds are
the release of stagnant humor and remote chilling, and
they are used as analgesic agent capable of relieving
cough, gastralgia, neuralgia, orchitis, colic, testicular
swelling and smallpox [6]. In India, the seeds are pow-
dered and administered to people with intestinal trouble.
The seeds also have the reputation of relieving neuralgic
pain in China. In recent studies, a variety of proantho-
cyanidins, flavonoid glycosides and polysaccharides were
identified from litchi seeds [7–9]. Some of these com-
pounds appeared to exhibit anti-neoplastic activities in
breast cancer, sarcoma, nasopharynx cancer, lung cancer,
cervical cancer and hepatocellular carcinoma cell lines
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[7, 8, 10, 11]. A possible mechanism may be due to the
inhibition of EGFR signaling and concomitant induc-
tion of intrinsic and extrinsic apoptosis pathways [10].
The hypothesis of the present study is the potential ap-
plication of litchi seed extract (LCSE) as an anti-lung
cancer agent because of the ability to target EGFR.
However, the detailed cellular and molecular mechanisms
of the suppressive effect of LCSE in NSCLC cells are still
unclear. In this study, we investigated the effects of LCSE
on two NSCLC cell lines, adenocarcinoma A549 and
large-cell carcinoma NCI-H661 cells, to evaluate the po-
tential of LCSE for the treatment of NSCLC.
Methods
Materials
Chemicals used for the preparation of buffers, cell-staining
fluorescent dyes or drugs such as proteinase inhibitor
cocktail, sodium orthovanadate, sodium fluoride, sodium
pyrophosphate, Triton X-100, ammonia persulfate, rhoda-
mine 123, propidium iodide, N,N,N’,N’-tetramethylethyle-
nediamine, sodium dodecyl sulfate (SDS), Tween 20, gallic
acid and catechin were obtained from Sigma (St. Louis,
MO, USA). Cell-culture materials such as Roswell Park
Memorial Institute (RPMI) media 1640, Dulbecco’s
Modified Eagle Medium (DMEM), fetal bovine serum
(FBS), L-glutamine, trypsin and antibiotics were purchased
from Gibco Ltd. (Paisley, UK). The protein assay kit
(bicinchoninic acid; BCA) was purchased from Pierce
(Rockford, IL, USA). Acrylamide was obtained from
Bio-Rad (Hercules, CA, USA). Polyvinylidene fluoride
(PVDF) membrane (Immobilon-P) was obtained from
Millipore (Bedford, MA, USA). Mouse monoclonal anti-
caspase 3, B cell lymphoma 2 (Bcl-2), cyclin B1, cyclin D1,
cyclin E and anti-MAP kinase (Erk-1/-2) antibodies and
rabbit anti-phosphor-Erk-1/-2 (The202/Tyr204) were pur-
chased from Zymed (San Francisco, CA, USA). Rabbit
polyclonal anti-human pan Akt, anti-phosphor-Akt (S473),
anti-EGFR, anti-phosphor-EGFR (phospho Tyr1092) and
anti-Kip1/p27, and goat polyclonal anti-pro-caspase 8, pro-
caspase 9, poly [ADP-ribose] polymerase (PARP), Bcl-2 as-
sociated protein X (Bax) antibodies and goat anti-rabbit,
anti-mouse and rabbit anti-goat secondary antibodies con-
jugated with horseradish peroxidase (HRP) were obtained
from R&D Systems (Minneapolis, MN, USA). Annexin V
conjugated with fluorescein isothiocyanate (FITC) was ob-
tained from Gene Research (Taipei, Taiwan).
Litchi seed extract
Hei Yeh Litchi (Litchi chinensis Sonn. var. Hei Yeh) fruit
were purchased from Rayfoung Co., Ltd (Chiayi, Taiwn)
and identified by Dr. Chih-Cheng Lin and Chih-Ping
Hsu using the Digital Fruit Genetic of Taiwan database
of the Agricultural Research Institute (Council of Agri-
culture, Executive Yuan of Taiwan) as a reference
(https://kmweb.coa.gov.tw/subject/ct.asp?xItem=176011&
ctNode=5525&mp=1&kpi=0&hashid=). Litchi seed extract
was obtained using the method described in a previous re-
port [12]. Briefly, litchi seeds dried in a 70 °C oven were
ground using a stainless-steel grinder (RT-02, Rong Tsong
Iron Factory Incorporation, Taiwan). Crude extract of litchi
seeds was obtained by mixing the powder with 70% ethanol
and refluxing overnight. The solution was then filtered and
centrifuged to remove any undissolved materials. The
supernatant was subsequently concentrated until no etha-
nol remained using a rotary evaporator under reduced
pressure and a water bath <35 °C, which was then freeze-
dried. The final crude extract was defined as LCSE. The
total levels of phenols, flavonoids and condensed
tannins were estimated using colorimetric methods as
described previously [12].
Cell culture
A549 and NCI-H661 cells were purchased from the
Bioresource Collection and Research Center in Taiwan.
A549 cells were established from lung carcinomatous
tissue from a 58-year-old Caucasian male, and the cell
type was identified as lung carcinoma. NCI-H661 cells
were derived from the lymph node of a patient with
large-cell lung cancer. These two cell lines were cultured
in 90% RPMI 1640 with 2 g/L sodium bicarbonate, 10%
heat-inactivated FBS, 25 U/mL penicillin and 25 μg/mL
streptomycin. The cells were incubated at 37 °C in a
95% air/5% CO2 water-saturated atmosphere. All experi-
ments were carried out using cell lines passaged between
5 and 20 times.
Cell proliferation assay
Cells were plated at 100,000 cells per 60-mm tissue cul-
ture dish and then treated with LCSE (0, 12.5, 25, 50, 100,
or 150 μg/mL) after approximately 18 h, when the cells
had become attached to the bottom of the plates. Cells
were incubated with LCSE for 24 h and then collected by
trypsinization, stained with trypan blue, and counted in
suspension in duplicate using a hemocytometer. Data
were obtained from the averages of three independent
experiments.
Clonogenic growth assay
200 cells were seeded in a 6-well plate and treated with
LCSE (1 ~ 50 μg/mL) then incubated at 37 °C for 14 days.
On day 14, the colonies were fixed in 70% ethanol and
stained with 0.2% crystal violet. Colonies of >50 cells
were counted and the colony-forming potential of LCSE-
treated NSCLC cells was expressed as a percentage of
colonies of the untreated cells.
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Cell-cycle analysis
As described in a previous report [13], LCSE-treated
cells were collected by trypsinization and then fixed in
70% ethanol at −20 °C for at least 30 min. Fixed cells
were reconstituted in phosphate-buffered saline and then
stained with propidium iodide solution (20 μg/mL propi-
dium iodide and 10 μg/mL RNase A) at 37 °C in the dark
for 30 min. The cell cycle of LCSE-treated cells was ex-
amined by flow cytometry (Becton Dickinson, CA) using
FL-2A to score the DNA content of cells. The numbers of
cells in the G1, S and G2/M cell-cycle phases were de-
termined using Modfit software and expressed as the
percentage of total cells (Verity Software House, Inc.,
Topsham, ME, USA).
Apoptosis
Apoptosis of LCSE-treated cells was analyzed using
annexin V-FITC labeling followed by flow cytometry, as
described in previous reports [14]. The treated cells were
trypsinized and suspended in binding buffer (10 mM
HEPES, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2). Cells
were stained with 2 μg/mL annexin V-FITC at room
temperature in the dark for 30 min. The fluorescence in-
tensity of the labeled cells was measured using FITC and
flow cytometry with FL-1H. Untreated cells served as the
negative control.
Mitochondrial membrane potential (Δψm)
Δψm, the mitochondrial membrane potential, indicates
the mitochondria membrane integrity in cells, and was
assessed as described by Hsu et al. [15]. Briefly, LCSE-
treated cells were collected, suspended at a density of
1 × 106 cells/mL in fresh medium and stained with
10 μg/mL rhodamine 123 for 30 min at 37 °C. Cells were
then washed twice with fresh medium, and the fluores-
cence intensity of the cells was immediately examined
by flow cytometry using FL-1H. Ten-thousand cells with-
out cell debris were analyzed, and the rhodamine 123-
negative cells were defined as those with a lower
fluorescence intensity than the untreated cells.
Immunoblotting
Ice-cold phosphate-buffered saline-washed cells were lysed
in homogenization buffer (10 mM Tris-HCl at pH 7.4,
2 mM EDTA, 1 mM EGTA, 50 mM NaCl, 1% Triton
X-100, 50 mM NaF, 20 mM sodium pyrophosphate,
1 mM sodium orthovanadate, and 1:100/v:v proteinase
inhibitor cocktail) at 4 °C for 30 min. Cell extracts were
obtained by ultracentrifugation of cell lysates at 100,000 × g
for 30 min at 4 °C. The protein concentration of the cell
extract was measured using a protein assay kit, and the
extracts were adjusted to 2 mg/mL with homogenization
buffer. For immunoblotting analysis, the proteins in
the cell extracts were separated by SDS-PAGE and
electrotransferred to PVDF membranes using semi-dry
blot apparatus (Bio-Rad) at 3 mA per cm2 of gel in
transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine,
and 20% methanol) at room temperature for 30 min.
The free protein-binding sites on the PVDF membrane
were saturated by incubation with 5% nonfat milk in
Tris-buffered saline with Tween 20 (TTBS) (20 mM
Tris at pH 7.4, 0.15 M NaCl, and 0.2% Tween 20) at
25 °C for 2 h. The membrane was then incubated with
0.1 μg/ml primary antibody in TTBS containing 3%
nonfat milk at 4 °C overnight and subsequently with
secondary antibody conjugated with peroxidase (1:1000)
at 25 °C for 1 h. The immunoblots were developed using
an enhanced chemiluminescence system, and the lumines-
cent images were captured using a Chemiluminescent
Detection System (Chemi Doc. XRS, Bio-Rad).
Statistical analysis
All data are expressed as means ± SD unless stated other-
wise. The differences between groups were calculated using
Student’s unpaired t-test. Dose-dependent effects were
calculated using simple linear regression. P < 0.05 was
regarded as statistically significant. All statistical analyses
were performed using SPSS version 17.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
The inhibitory effect of LCSE on the growth of NSCLC cell
lines
The proliferation and colony-forming activities of A549
and NCI-H661 cells were both inhibited by LSCE treat-
ment. As shown in Fig. 1a, the cell survival ratio de-
creased gradually in both treated cell lines as compared
to the untreated cells after 24 h. The sensitivity of the
A549 cell line to LCSE was greater than that of NCI-H661
when the dose of LCSE was higher than 25 μg/mL.
MRC-5, a human normal lung cell line, was not remark-
ably influenced by treatment with LCSE at dosage lower
than 50 μg/mL. In cancer cell lines, LCSE exhibited ap-
proximately 60% growth inhibition with dosage of
100 μg/mL LCSE, while the survival rate decreased to
20% in A549 and 30% in NCI-H661 cells after treat-
ment with 150 μg/mL of LCSE. Growth inhibition of
NSCLC cells caused by LCSE treatment was similarly
observed in colony-forming activity. As shown in Fig. 1b,
the number of colonies gradually reduced as the dosage of
LCSE increased. The sensitivities of the two cell lines to
LCSE in this assay had similar trend; however, NCI-H661
cells exhibited greater sensitivity than A549 cells in the
dosage of 25 μg/mL and 50 μg/mL (P < 0.01). These re-
sults demonstrated that LCSE exerted significant inhib-
ition on both the proliferation and colony formation in
these two NSCLC cell lines, whereas the cytotoxicity ef-
fects in normal lung cell line were relatively low.
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Cell-cycle arrest at the G1 or G2/M phase by LCSE
treatment
The cell-cycle distribution of LCSE-treated NSCLC cells
is shown in Fig. 2a. A549 cells exhibited increasing per-
centage of G1-phase cells upon LSCE treatment with
dosage greater than 12.5 μg/mL. The percentage of total
control cells increased from 58.93 to 66.04% as the dos-
age elevated from 12.5 μg/mL to 50 μg/mL of LCSE. In-
creasing numbers of cells of G2/M-phase were also
noted, from 9.99% of the total control cells to 26.41% in
the group of 150 μg/mL LCSE-treated cells. Regarding
to the number of S-phase, LCSE-treated cells gradually
decreased from 31.07% of the total control cells of
12.5 μg/mL to 11.8% of 150 μg/mL in LCSE-treated
cells. NCI-H661 cells also showed a trend of gradual in-
crease in G2/M-phase cells, from 6.01% of the total con-
trol cells to 31.54% of 150 μg/mL LCSE-treated cells,
but the numbers of cells in G1-phase were reduced. The
changes in cell-cycle controlling proteins are shown in
Fig. 2b. The levels of cell-cycle controlling proteins, in-
cluding cyclin D1, E, and B1, decreased gradually, and
the level of Kip1/p27 increased after LCSE treatment in
A549 cells. The levels of cyclin E and B1 decreased grad-
ually after LCSE treatment in NCI-H661, but the level of
cyclin D increased. The elevation of Kip1/p27 level in
NCI-H661cells treated with dosage of LCSE greater than
25 μg/mL was also noted. These results indicated that
LCSE arrested A549 cells in the G1 phase of the cell
cycle and concomitantly inhibited G2/M progression,
possibly by suppressing the expressions of cyclin D1, E
and B1 and increasing the Kip1/p27 level. The suppres-
sion of cyclin with elevation of Kip1/p27 accounted for
the LCSE arresting NCI-H661 cell in the G2/M phase of
the cell cycle.
Apoptosis induction by LCSE in NSCLC cells
LCSE-treated A549 and NCI-H661 cells were stained
with annexin V-FITC or rhodamine 123, and were ana-
lyzed by flow cytometry to assess the numbers of apop-
totic cells and the mitochondrial integrity. Compared with
the control groups, the number of annexin V-positive cells
in both LCSE-treated NSCLC cell lines gradually in-
creased according to the dosage elevation. A549 was
shown to be less affected by LCSE-induced apoptosis.
Contrary to A541, the increasing percentage of annexin
V-positive cells from 12% in 25 μg/mL group to 40% in
150 μg/mL group of LCSE treatment, approximately 14%
of annexin V-positive cells were observed in 12.5 μg/mL
group, and increased to 64% in 150 μg/mLgroup of
LCSE-treated NCI-H661 cells (Fig. 3a). To investigate
whether the induction of apoptosis by LCSE in NSCLC
cells involved the loss of mitochondrial integrity, Δψm
in LCSE-treated cells was analyzed. As shown in Fig. 3b,
the percentages of rhodamine 123-negative cells in the
control groups were all below 5% of the total cells. After
treatment with LCSE, this percentage increased signifi-
cantly (P < 0.05), from 13% in the group of 12.5 μg/mL to
around 80% in the 150 μg/mL group of LCSE-treated
NCI-H661 cells. The percentage of rhodamine 123-
negative A549 cells also increased from around10% in
25 μg/mL group to around 25% in the 150 μg/mL LCSE
treatment. Immunoblotting analysis revealed that the
levels of pro-caspase 8, 9 and 3 were decreased when
treated with dosage greater than 25 μg/mL LCSE, while
the caspase 3 substrate PARP showed increasing levels
Fig. 1 Dose-dependent responses of A549, NCI-H661 and MRC-5
cells to LCSE. Cells were treated with increasing concentrations of
LCSE as indicated and then incubated at 37 °C for 24 h to obtain a
dose-dependent response. Viable cells were stained with trypan blue
and counted under a microscope. Cell viability was expressed as the
percentage of untreated cells. a. Colony formation of LCSE-treated
cells was assessed by seeding 200 cells in a 6-well plate and treating
with LCSE (1 ~ 50 μg/mL), followed by incubation at 37 °C for 14 days.
On day 14, the colonies were fixed in 70% ethanol and stained with
0.2% crystal violet. Colonies of >50 cells were counted and the col-
ony-forming potential of LCSE-treated NSCLC cells was expressed as
the percentage of colonies of the untreated cells (b). Data are the
average of three independent experiments and are expressed as
means ± SD. *P < 0.05 (compared with untreated control); # P <0.01
(compared within A549 and NCI-H661)
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of cleaved fragments under the same treatment condi-
tions in A549 cells (Fig. 3b). The level of apoptosis-
promoting protein Bax was increased in A549 cells
when treated with greater than 50 μg/mL LCSE. How-
ever, the level of anti-apoptosis protein Bcl-2 was sus-
tained under LCSE treatment in A549 cells. The levels
of pro-caspase 8, 9 and 3 were gradually decreased and
the caspase 3 substrate PARP showed increasing levels
of cleaved fragments in LCSE treated NCI-H661 cells
that were similar to A549 cells with dosage greater than
12.5 μg/mL. The level of apoptosis-promoting protein
Bax was increased in NCI-H661 cells under treatment
with dosage greater than 25 μg/mL LCSE, while the
level of anti-apoptosis protein Bcl-2 was decreased under
treatment with dosage greater than 50 μg/mL LCSE in
NCI-H661.
LCSE disturbed EGFR signaling in NSCLC cells
EGFR protein and its phosphorylated tyrosine level were
gradually decreased in A549 cells treated with dosage
greater than 25 μg/mL LCSE (Fig. 4). The expression in
the protein level of EGFR was unremarkable, while the
phosphor-EGFR level was decreased in cells treated with
dosage greater than 25 μg/mL of LCSE in NCI-H661
cells. Both the protein level and phosphorylation level of
EGFR downstream signal protein Akt were decreased in
the two LCSE-treated NSCLC cell lines. The protein
levels of Erk-1 and −2 were not altered under LCSE
Fig. 2 Cell-cycle arrest in NSCLC cells by LCSE. LCSE-treated cells were incubated at 37 °C for 24 h, fixed in 70% alcohol and stained with propidium
iodide, then analyzed by flow cytometry, as described in Materials and Methods. The same LCSE-treated cells were lysed and the cell proteins
separated by SDS-PAGE followed by immunoblotting to show proteins as indicated, with the beta-actin level as the loading control. Protein
levels were quantified using Image Lab software (Bio-Rad) according to the density of each band on the immunoblotting image, normalized
to the reference band (β-actin) and presented as the fold change of the untreated control. The cell-cycle distributions of LCSE-treated A549
and NCI-H661 cells are shown in (a), respectively, and the cell-cycle-associated proteins are shown in (b). The data reported are the percentages of total
cells from the averages of three independent experiments and are expressed as means ± SD. *P < 0.05
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Fig. 3 LCSE induced apoptosis in NSCLC cells. LCSE-treated cells were incubated at 37 °C for 24 h, stained with annexin V conjugated with FITC
(a) or rhodamine 123 (b), then analyzed by flow cytometry, as described in Materials and Methods. Cell protein lysates from LCSE-treated cells
were separated by SDS-PAGE, transferred to PVDF membranes, and immunoblotted to show proteins as indicated. Protein levels were quantified
and normalized using the density of the beta-actin level as the loading control (c). The data reported are the averages of three independent
experiments and are expressed as means ± SD. * P < 0.05
Fig. 4 Immunoblots of EGFR signaling in LCSE-treated NSCLC cells. Cells were treated with increasing concentrations of LCSE as indicated and
then incubated at 37 °C for 24 h. Cell protein lysates from A549 and NCI-H661 cells were separated by SDS-PAGE, transferred to PVDF membranes,
and immunoblotted to show proteins and their phosphorylation levels, with the beta-actin level used as the loading control
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treatment below 50 μg/mL but were slightly decreased
under treatment with greater than 100 μg/mL of LCSE
in A549 cells. The levels of phosphor-Erk-1 and −2 were
decreased in cells treated with dosage greater than
25 μg/mL of LCSE in A549 cells. The levels of these two
Erk proteins were slightly increased when treated with
dosage below 25 μg/mL of LCSE and were decreased
under the dosage greater than 50 μg/mL in NCI-H661.
The levels of phosphor-Erk-1 and −2 were significantly
decreased under treatment with dosage greater than
12.5 μg/mL LCSE and were undetectable under treatment
with dosage of 150 μg/mL LCSE in NCI-H661 cells.
Discussion
Previous studies have revealed inhibitory effects of LCSE
on the growth of several types of malignant cells, includ-
ing lung cancer [8, 11]. However, the exact mechanisms
responsible for the anti-cancer activity of LCSE are still
not fully understood. In this study, we comprehensively
investigated the possible cellular and molecular mecha-
nisms of the effects of LCSE in two NSCLC cancer cell
lines, A549 and NCI-H661. The results demonstrated
that LCSE suppressed the EGFR protein and its phos-
phorylation levels, then downregulated the downstream
signaling, such as Erk-1/-2 and Akt signaling. These ef-
fects resulted in the suppression of some cyclins, eleva-
tion of the expressions of Kip1/p27 and Bax protein,
and activation of caspase-8, −9 and −3, which induced
cell-cycle arrest and apoptosis in NSCLC cells.
EGFR is the predominant target of therapy in NSCLC,
as this proto-oncogene is always overexpressed and plays
a key role in the growth of NSCLC [16]. Activated EGFR
stimulates its two major downstream signaling pathways,
Ras and phosphatidyl inositol 3 kinase (PI3K), then acti-
vates Erk-1/-2 and Akt signaling. Erk-1/-2 translocates
to the nucleus and triggers expression of cell-cycle-
controlling proteins. Akt could phosphorylate Bad and
dissociate Bad with Bcl-2, which suppresses the activity
of Bax and leads to the avoidance of apoptosis in cancer
cells [10]. In this study, we demonstrated the elevation
of the number of apoptotic cells, and the reduction in
mitochondria membrane potential in both treated A549
and NCI-H661cells with LCSE. The expression of Bax
protein was upregulated in both cells, and Bcl-2 was
downregulated in NCI-H661 cells. These results indi-
cated that the inhibitory effect of LCSE on EGFR signal-
ing directly effected the Akt activity, then triggered an
intrinsic apoptosis mechanism to induce apoptotic death
in both NSCLC cells. A previous report indicated that
LCSE also triggers the other extrinsic apoptosis pathway
to induce apoptosis [10]. Our results appeared to sup-
port this viewpoint, with the level of procaspase 8 being
gradually decreased after LCSE treatment in the NSCLC
cells. From our results and those of other studies, we
can conclude that LCSE-induced apoptotic death in
NSCLC cells arises from triggering both the intrinsic
and extrinsic apoptosis pathways.
Although LCSE induced apoptosis in both tested
NSCLC cells, the sensitivity differed between the two
cells. NCI-H661 cells were more sensitive than A549
cells in the treatment with LCSE which was demonstrated
by the number of annexin V-positive cells, the mitochon-
dria potential loss and the Bax and Bcl-2 protein levels. As
shown in Fig. 3, the number of annexin V-positive cells
and the mitochondria membrane potential loss of cells
were elevated more than 60% of the total NCI-H661
cells under LCSE treatment with dosage of 100 and
150 μg/mL. In the A549 cells, only less than 40% of the
total number of cells underwent apoptosis. Although
the Bax level in LCSE-treated cells was elevated, the
Bcl-2 level in NCI-H661 cells was dramatically dimin-
ished under dosage more than 50 μg/mL LCSE treatment,
whereas the level of Bcl-2 in A549 cells was sustained.
The balance of Bax and Bcl-2 in cells plays a pivotal role
in the regulation of apoptosis in LCSE-treated cancer
cells which was highlighted in our previous report and
other studies [8, 11, 12]. LCSE-treated NCI-H661 cells
contained a greater number of apoptotic cells indicating
that the mechanism of the growth inhibition effect of
LCSE in the cells is mitochondria-mediated apoptosis,
which mainly arised from elevation of the Bax level and
downregulation of the Bcl-2 level.
Our previous study revealed that LCSE arrested cancer
cells in the G2/M phase by reducing the expression of
cyclin B1 [12]. In this study, we further confirmed this
effect in the two tested NSCLC cells. The number of
NCI-H661 cells in the G2/M phase was elevated under
treatment with LCSE with dosage more than 12.5 μg/mL.
However, the change of G2/M phase only gradually in-
creased to a quarter of A549 cells under LCSE treament
with dosage of 150 μg/mL. These results suggest the effect
of cell cycle arrest in G2/M phase was more predominant
in NCI-H661 cells. Previous studies revealed that Erk ac-
tivity is an important factor in G2/M-phase progression in
the cell cycle, and the M phase is nearly twice as long in
mammalian cultured cells when Erk is inhibited during
G2/M transition [17, 18]. In the report of Lin et al., they
indicated that downregulation of the EGFR/Erk/c-fos sig-
naling pathway can inhibit the COX-2 level and activate
Kip1/p27 to induce G2/M cell-cycle arrest in oral carcin-
oma cells [19]. Another study revealed that EGF could ac-
tivate Akt and triggered CK2a and HDAC2 expression;
whereas inhibition of Akt or CK2a and concomitant sup-
pression of the expressions of CDC25c and cyclin B would
arrest cells in the G2/M phase [20]. Our results proved
that LCSE inhibited the activities of EGFR, Erk-1/-2 and
Akt and concomitantly suppressed the level of cyclin B;
therefore, indicating that the LCSE-induced G2/M-phase
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arrest might arise from the reduction of EGFR signaling
and control of cyclin B in NSCLC cells.
However, LCSE also disturbed the process of the G1
phase progression in A549 cells, including suppression
of the levels of cyclin D1 and E and elevation of the level
of Kip1/p27. Our results confirmed that LCSE-treated
A549 cells expressed a greater number of G1-phase cells
as compared to control cells. Recent studies proved that
suppression of the EGFR/Ras/MEK/Erk and PI-3 K/Akt
pathways could lead to cell-cycle arrest in the G1 phase
[21, 22], mainly through upregulation of Kip/p27 and
downregulation of cyclin E [23, 24]. Earlier reports also
pointed out that Erk regulates cyclin D1 transcription
and cyclin D1/CDKs assembly and triggers G1 to S tran-
sition in the cell cycle [25–29]. Since LCSE reduced
EGFR signaling, downregulated Erk-1/-2 and Akt, and
arrested the G1 phase in A549 cells, our results indi-
cated a possible novel role of LCSE in the control of
lung adenocarcinoma cells in terms of cell-cycle pro-
gression from the G1 phase to the S phase. However,
the effect of G1 phase arrest was not fully apparent in
LCSE-treated NCI-H661 cells, in which cyclin D1 was
elevated under LCSE treatment. The reasons for these
results need further investigation.
Conclusion
Our results revealed that LCSE inhibited EGFR activity
and protein expression in two NSCLC cells, concomitantly
reduced the downstream Akt and Erk-1/-2 signaling, then
downregulated Bcl-2, cyclin B1 and cyclin E and elevated
Kip1/p27 and Bax. In addition to growth inhibition in both
cell lines, these events resulted in cell arrest at the G2/M
phase of the cell cycle and lead to apoptotic death. This
study was the first to describe the detailed mechanisms of
LCSE in NSCLC and suggested LCSE may be a novel
herbal agent that acts through the inhibition of EGFR sig-
naling to induce cytotoxicity in NSCLC. It would be intri-
guing to examine whether the findings of this study could
be replicated in an animal model of NSCLC and further in-
vestigation is warranted.
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